Role of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease Pathogenesis: Updates and Perspectives
Immuno · 15.04.2025 · 5 (2) · 13
DOI: 10.3390/immuno5020013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immuno, online erschienen am 15.04.2025. Verfasst von Pankush und 8 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is a chronic, debilitating condition that affects the lungs and airways. It is characterized by persistent bronchitis, a condition exemplified by the inflammation of the bronchial tubes, the hypersecretion of mucus, emphysema, and the destruction of the airway parenchyma. The combination of these conditions leads to persistent tissue damage, pulmonary fibrosis, and ongoing inflammation of the airways. The inflammatory response in COPD is a complex process that is orchestrated by a wide range of immune cells. These include lung epithelial cells, monocytes, macrophages, neutrophils, eosinophils, and T and B lymphocytes, among others. These cells work together to produce a wide range of inflammatory biomarkers that are involved in the pathogenesis of COPD. Some of the key inflammatory biomarkers that have been identified in COPD include a variety of cytokines, the C-reactive protein/serum albumin ratio, fibrinogen, soluble receptor for advanced glycation endproducts, club/clara cells in the lungs with a molecular weight of 16 kDa, surfactant protein D, adiponectin, reactive oxygen species, and proteases. This review aims to provide a comprehensive overview of the role of immune cells and key inflammatory biomarkers in the development and progression of COPD. It will delve into the intricacies of the inflammatory response in COPD, exploring the various cell types and biomarkers that are involved in this process. By understanding the underlying mechanisms that drive COPD, we can better develop targeted treatments that can help to alleviate the symptoms of COPD.
Zitieren
APA
Pankush, Bharti, K., Pandey, R., Srivastava, N., Kashyap, S., Kumar, D., Kumar, L., Suman, S. K., & Patel, S. K. S. (2025). Role of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease Pathogenesis: Updates and Perspectives. Immuno, 5(2), 13. https://doi.org/10.3390/immuno5020013
Vancouver
Pankush, Bharti K, Pandey R, Srivastava N, Kashyap S, Kumar D, et al. Role of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease Pathogenesis: Updates and Perspectives. Immuno. 2025;5(2):13. doi:10.3390/immuno5020013
BibTeX
@article{Pankush2025,
author = {Pankush and Bharti, Khushboo and Pandey, Rohit and Srivastava, Namita and Kashyap, Shashank and Kumar, Deepak and Kumar, Lokender and Suman, Sunil K. and Patel, Sanjay K. S.},
title = {Role of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease Pathogenesis: Updates and Perspectives},
journal = {Immuno},
year = {2025},
volume = {5},
number = {2},
pages = {13},
doi = {10.3390/immuno5020013}
}
EUVIMED